|
1
|
Sanz MA, Montesinos P, Vellenga E, Rayón
C, de la Serna J, Parody R, Bergua JM, León A, Negri S, González M,
et al: Risk-adapted treatment of acute promyelocytic leukemia with
all-trans retinoic acid and anthracycline monochemotherapy:
Long-term outcome of the LPA 99 multicenter study by the PETHEMA
group. Blood. 112:3130–3134. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lo-Coco F, Avvisati G, Vignetti M, Breccia
M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia
G, et al: Front-line treatment of acute promyelocytic leukemia with
AIDA induction followed by risk-adapted consolidation for adults
younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA
group. Blood. 116:3171–3179. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Iland H, Bradstock K, Seymour J, Hertzberg
M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge
S, et al: Results of the APML3 trial incorporating
all-trans-retinoic acid and idarubicin in both induction and
consolidation as initial therapy for patients with acute
promyelocytic leukemia. Haematologica. 97:227–234. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Burnett AK, Russell NH, Hills RK, Bowen D,
Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, et al:
Arsenic trioxide and all-trans retinoic acid treatment for acute
promyelocytic leukaemia in all risk groups (AML17): Results of a
randomised, controlled, phase 3 trial. Lancet Oncol. 16:1295–1305.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Platzbecker U, Avvisati G, Cicconi L,
Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F,
Efficace F, et al: Improved outcomes with retinoic acid and arsenic
trioxide compared with retinoic acid and chemotherapy in
non-high-risk acute promyelocytic leukemia: Final results of the
Randomized Italian-German APL0406 trial. J Clin Oncol. 35:605–612.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Iland HJ, Collins M, Bradstock K, Supple
SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell
LJ, et al: Use of arsenic trioxide in remission induction and
consolidation therapy for acute promyelocytic leukaemia in the
Australasian Leukaemia and Lymphoma group (ALLG) APML4 study: A
non-randomised phase 2 trial. Lancet Haematol. 2:e357–e366.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Abaza Y, Kantarjian H, Garcia-Manero G,
Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W,
Pierce S, et al: Long-term outcome of acute promyelocytic leukemia
treated with all-trans-retinoic acid, arsenic trioxide, and
gemtuzumab. Blood. 129:1275–1283. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sanz MA, Lo Coco F, Martin G, Avvisati G,
Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD,
Liso V, et al: Definition of relapse risk and role of
nonanthracycline drugs for consolidation in patients with acute
promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA
cooperative groups. Blood. 96:1247–1253. 2000.PubMed/NCBI
|
|
10
|
De Botton S, Chevret S, Coiteux V, Dombret
H, Sanz M, San Miguel J, Caillot D, Vekhoff A, Gardembas M,
Stamatoulas A, et al: Early onset of chemotherapy can reduce the
incidence of ATRA syndrome in newly diagnosed acute promyelocytic
leukemia (APL) with low white blood cell counts: Results from APL
93 trial. Leukemia. 17:339–342. 2003.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Montesinos P, Rayón C, Vellenga E, Brunet
S, González J, González M, Holowiecka A, Esteve J, Bergua J,
González JD, et al: Clinical significance of CD56 expression in
patients with acute promyelocytic leukemia treated with all-trans
retinoic acid and anthracycline-based regimens. Blood.
117:1799–1805. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Breccia M, Mazzarella L, Bagnardi V,
Disalvatore D, Loglisci G, Cimino G, Testi AM, Avvisati G, Petti
MC, Minotti C, et al: Increased BMI correlates with higher risk of
disease relapse and differentiation syndrome in patients with acute
promyelocytic leukemia treated with the AIDA protocols. Blood.
119:49–54. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu
YM, Li JM, Tang W, Zhao WL, Wu W, et al: Long-term efficacy and
safety of all-trans retinoic acid/arsenic trioxide-based therapy in
newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci
USA. 106:3342–3347. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang
JX, Chen SJ and Huang XJ: Long-term survival of acute promyelocytic
leukaemia patients treated with arsenic and retinoic acid. Br J
Haematol. 174:820–822. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rezuke WN, Anderson C, Pastuszak WT,
Conway SR and Firshein SI: Arsenic intoxication presenting as a
myelodysplastic syndrome: A case report. Am J Hematol. 36:291–293.
1991.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Firkin F: Carcinogenic risk of retained
arsenic after successful treatment of acute promyelocytic leukemia
with arsenic trioxide: A cause for concern? Leuk Lymphoma.
55:977–978. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu
YM, Shi JY, Zheng PZ, Yan H, Liu YF, et al: All-trans retinoic
acid/As2O3 combination yields a high quality remission and survival
in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci
USA. 101:5328–5335. 2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Estey E, Garcia-Manero G, Ferrajoli A,
Faderl S, Verstovsek S, Jones D and Kantarjian H: Use of all-trans
retinoic acid plus arsenic trioxide as an alternative to
chemotherapy in untreated acute promyelocytic leukemia. Blood.
107:3469–3473. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Powell BL, Moser B, Stock W, Gallagher RE,
Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, et
al: Arsenic trioxide improves event-free and overall survival for
adults with acute promyelocytic leukemia: North American leukemia
intergroup study C9710. Blood. 116:3751–3757. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Junbo Ge and Yongjian Xu: Internal
Medicine. 8th Edition. People's Medical Publishing house, Beijing,
pp928-932, 2014.
|
|
21
|
Ye Y, Gaugler B, Mohty M and Malard F: Old
dog, new trick: Trivalent arsenic as an immunomodulatory drug. Br J
Pharmacol. 177:2199–2214. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: Revised recommendations of the international working
group for diagnosis, standardization of response criteria,
treatment outcomes, and reporting standards for therapeutic trials
in acute myeloid leukemia. J Clin Oncol. 21:4642–4649.
2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lo Coco F, Diverio D, Avvisati G, Petti
MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C,
Selleri C, et al: Therapy of molecular relapse in acute
promyelocytic leukemia. Blood. 94:2225–2229. 1999.PubMed/NCBI
|
|
24
|
Zhang X, Zhang H, Chen L, Wang M, Xi J,
Liu X, Xie M, Li D, Gulati ES, Gong S and Wang H: Arsenic trioxide
and all-trans retinoic acid (ATRA) treatment for acute
promyelocytic leukemia in all risk groups: Study protocol for a
randomized controlled trial. Trials. 19(476)2018.PubMed/NCBI View Article : Google Scholar
|
